Company intelligence / Profile preview

TheraVitae

Ownership: Private
Development stage: Phase 2

Overview

TheraVitae's lead product ACP-01 has completed Phase 2 trials for Peripheral Arterial Disease. The company has been recognized for its adult stem cell therapies for cardiovascular disease.

Therapeutic areas: Cardiovascular
Modalities: Adult stem cellsCellular therapy
Industry: Biotech

Drug pipeline

1 asset

ACP-01

Phase 2

Indications: Critical limb ischemia

Partnerships

Hemostemix, Inc.

Beyond the preview

Go deeper on TheraVitae.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraVitae.

Explore the full profile